31 results
Keyword Docetaxel Remove keyword
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Medicine type
Additional monitoring Remove Additional monitoring filter
Generic Remove Generic filter
Orphan medicine Remove Orphan medicine filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Kabi
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 22/05/2012,
, Revision: 13, Authorised, Last updated: 19/05/2020
initial authorisation) Docetaxel Kabi docetaxel On 15 March 2012 the Committee … for the medicinal product Docetaxel Kabi 20 mg/ml concentrate … The active substance of Docetaxel Kabi is … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Accord
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 22/05/2012,, Revision: 13, Authorised, Last updated: 08/04/2020
Package size EU/1/12/769/001 Docetaxel Accord 20 mg/1 ml Concentrate … 1 vial EU/1/12/769/002 Docetaxel Accord 80 mg/4 ml Concentrate … 1 vial EU/1/12/769/003 Docetaxel Accord 160 mg/8 ml Concentrate … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Teva
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/01/2010,, Revision: 17, Authorised, Last updated: 05/08/2019
summary for the public Docetaxel Teva docetaxel This is a summary of the … assessment report (EPAR) for Docetaxel Teva. It explains how the … the conditions of use for Docetaxel Teva. What is … -
List item
Human medicine European public assessment report (EPAR): Zercepac
trastuzumab, Breast Neoplasms, Stomach Neoplasms
Date of authorisation: 27/07/2020,
, 
, Authorised, Last updated: 28/07/2020
medicines: paclitaxel or docetaxel, or with another type of medicine … another cancer medicine, docetaxel. A response to treatment after … -
List item
Human medicine European public assessment report (EPAR): Kanjinti
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 16/05/2018,, , Revision: 6, Authorised, Last updated: 29/11/2019
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Ontruzant
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017,, , Revision: 5, Authorised, Last updated: 19/05/2020
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Ogivri
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 12/12/2018,, , Revision: 3, Authorised, Last updated: 18/03/2020
medicines: with paclitaxel or docetaxel, or with another type of medicine … medicines (paclitaxel or docetaxel). A response to treatment after … -
List item
Human medicine European public assessment report (EPAR): Herzuma (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 08/02/2018,, , Revision: 9, Authorised, Last updated: 26/10/2020
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Trazimera
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/07/2018,, , Revision: 6, Authorised, Last updated: 09/07/2020
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Tecentriq (updated)
atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/09/2017,, Revision: 11, Authorised, Last updated: 19/10/2020
Tecentriq is more effective than docetaxel (another cancer medicine … average while those given docetaxel lived for 10 months. In a … 10 months for patients on docetaxel. In another main study of … -
List item
Human medicine European public assessment report (EPAR): Capecitabine Accord
capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012,
, , Revision: 12, Authorised, Last updated: 03/08/2020
Capecitabine Accord is used with docetaxel (another cancer medicine … -
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015,, Revision: 28, Authorised, Last updated: 24/08/2020
another cancer medicine called docetaxel (around 8 months) and the … -
List item
Human medicine European public assessment report (EPAR): Capecitabine Medac
capecitabine, Colorectal Neoplasms
Date of authorisation: 19/11/2012,, , Revision: 10, Authorised, Last updated: 05/08/2020
Capecitabine medac is used with docetaxel (another cancer medicine … -
List item
Human medicine European public assessment report (EPAR): Ecansya (previously Capecitabine Krka)
capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012,, , Revision: 12, Authorised, Last updated: 31/07/2020
body). Ecansya is used with docetaxel (another cancer medicine … -
List item
Human medicine European public assessment report (EPAR): Capecitabine Teva
capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012,, , Revision: 13, Authorised, Last updated: 29/07/2020
Capecitabine Teva is used with docetaxel (another cancer medicine … -
List item
Human medicine European public assessment report (EPAR): Onivyde pegylated liposomal (previously known as Onivyde) (updated)
irinotecan hydrochloride trihydrate, Pancreatic Neoplasms
Date of authorisation: 14/10/2016,
, Revision: 7, Authorised, Last updated: 15/10/2020
-
List item
Human medicine European public assessment report (EPAR): Imatinib Actavis
imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Hypereosinophilic Syndrome, Dermatofibrosarcoma
Date of authorisation: 17/04/2013,, Revision: 12, Authorised, Last updated: 10/09/2020
-
List item
Human medicine European public assessment report (EPAR): Xofigo
radium Ra223 dichloride, Prostatic Neoplasms
Date of authorisation: 13/11/2013,, Revision: 11, Authorised, Last updated: 18/05/2020
-
List item
Human medicine European public assessment report (EPAR): Zejula
Niraparib (tosylate monohydrate), Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
Date of authorisation: 16/11/2017,, , Revision: 10, Authorised, Last updated: 27/08/2020
-
List item
Human medicine European public assessment report (EPAR): Tagrisso (updated)
osimertinib mesylate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016,, 
, Revision: 12, Authorised, Last updated: 16/10/2020
-
List item
Human medicine European public assessment report (EPAR): Zykadia
ceritinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/05/2015,, Revision: 13, Authorised, Last updated: 12/02/2020
-
List item
Human medicine European public assessment report (EPAR): Sylvant
siltuximab, Giant Lymph Node Hyperplasia
Date of authorisation: 22/05/2014,, , Revision: 10, Authorised, Last updated: 08/10/2019
-
List item
Human medicine European public assessment report (EPAR): Yescarta
axicabtagene ciloleucel, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018,, , Revision: 6, Authorised, Last updated: 26/06/2020
-
List item
Human medicine European public assessment report (EPAR): Farydak
panobinostat lactate anhydrous, Multiple Myeloma
Date of authorisation: 28/08/2015,, Revision: 9, Authorised, Last updated: 16/06/2020
-
List item
Human medicine European public assessment report (EPAR): Caprelsa
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,, 
, Revision: 17, Authorised, Last updated: 24/01/2020